GlassScriptPhysician profile
Kelly Tillman
NPI 1518337278
$5,807.71
in general payments reported to CMS, 2019-2025
48 companies · $1,242 in 2025
The $1,242 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $900 · 2022: $832 · 2023: $1,704 · 2024: $1,130 · 2025: $1,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,075.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,011.32 | 2021-2025 | |
| Glaxosmithkline, LLC. | $635.30 | 2021-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Astrazeneca Pharmaceuticals LP | $554.07 | 2021-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $421.83 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $343.65 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $314.18 | 2021-2024 | Repatha, Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $238.27 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $195.01 | 2021-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $166.42 | 2024-2025 | Caplyta |
| Pfizer INC. | $148.99 | 2023-2025 | |
| Tris Pharma INC | $139.07 | 2023-2024 | Dyanavel Xr |
| Corium, LLC | $123.14 | 2021-2024 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.83 | 2024-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $93.05 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $90.30 | 2023-2025 | Gvoke Hypopen |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $76.84 | 2023-2024 | Crysvita |
| Inspire Medical Systems, INC. | $74.22 | 2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $70.97 | 2022-2025 | Rexulti |
| Genzyme Corporation | $64.75 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.11 | 2021 | |
| Vanda Pharmaceuticals INC. | $63.09 | 2025 | Fanapt |
| Exact Sciences Corporation | $61.55 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi Pasteur INC. | $57.07 | 2021-2023 | |
| Collegium Pharmaceutical, INC. | $49.37 | 2025 | Jornay Pm |
| Lundbeck LLC | $48.63 | 2023-2025 | Rexulti |
| Corcept Therapeutics | $44.69 | 2025 | Korlym |
| Philips North America LLC | $41.86 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Ultragenyx Pharmaceutical INC. | $40.81 | 2021-2022 | |
| Redhill Biopharma INC. | $39.88 | 2021 | |
| Abbott Laboratories | $39.32 | 2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $38.52 | 2021 | |
| Eisai INC. | $33.33 | 2021 | |
| Hologic Sales and Service, LLC | $30.52 | 2023 | Thinprep 2000 Processor, Affirm Prone Biopsy System |
| Merck Sharp & Dohme LLC | $27.61 | 2021 | |
| Esperion Therapeutics, INC. | $26.68 | 2023-2025 | Nexletol |
| Boston Scientific Corporation | $26.41 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.66 | 2022 | |
| Nevro Corp. | $22.09 | 2023 | Senza |
| Zealand Pharma US, INC. | $19.28 | 2021 | |
| Ardelyx, INC. | $18.96 | 2025 | Ibsrela |
| Scynexis, INC. | $17.72 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.37 | 2024 | Voquezna |
| Tonix Medicines, INC. | $17.19 | 2025 | Tonmya |
| Idorsia Pharmaceuticals US INC | $15.85 | 2023 | Quviviq |
| Amarin Pharma, INC. | $14.05 | 2021 | |
| Dexcom, INC. | $12.90 | 2021 | |
| Seqirus USA INC | $12.19 | 2021 | |
| Insulet Corporation | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Tillman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.